Dimensional Fund Advisors LP Increases Stock Position in Ingevity Corporation $NGVT

Key Points

• Dimensional Fund Advisors increased its Ingevity stake by 3.0% in the first quarter, bringing its holdings to 798,709 shares worth approximately $56.9 million. Institutional investors and hedge funds collectively own 91.59% of NGVT.
• Several other major investors significantly expanded their positions, including Principal Financial Group, UBS Asset Management, Simcoe Capital Management, Boston Partners and Bessemer Group.
• Ingevity beat quarterly earnings expectations, reporting $1.74 in EPS versus $1.33 expected and revenue of $314.1 million. Despite the earnings beat, analysts maintain a consensus “Hold” rating with an average price target of $80.

Dimensional Fund Advisors LP grew its stake in Ingevity Corporation (NYSE:NGVT - Free Report) by 3.0% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 798,709 shares of the company's stock after acquiring an additional 23,219 shares during the period. Dimensional Fund Advisors LP owned about 2.26% of Ingevity worth $56,889,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the stock. Principal Financial Group Inc. increased its holdings in Ingevity by 269.9% in the 4th quarter. Principal Financial Group Inc. now owns 652,237 shares of the company's stock valued at $38,599,000 after purchasing an additional 475,907 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Ingevity by 311.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company's stock valued at $23,769,000 after buying an additional 454,579 shares during the period. Simcoe Capital Management LLC lifted its stake in Ingevity by 188.8% during the 2nd quarter. Simcoe Capital Management LLC now owns 624,935 shares of the company's stock worth $26,928,000 after acquiring an additional 408,508 shares in the last quarter. Boston Partners lifted its stake in Ingevity by 141.6% during the 4th quarter. Boston Partners now owns 620,360 shares of the company's stock worth $36,719,000 after acquiring an additional 363,584 shares in the last quarter. Finally, Bessemer Group Inc. boosted its holdings in Ingevity by 465.9% during the 1st quarter. Bessemer Group Inc. now owns 314,739 shares of the company's stock valued at $22,419,000 after acquiring an additional 259,124 shares during the period. 91.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Ingevity news, SVP Terrance M. Dyer sold 496 shares of the firm's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $68.49, for a total value of $33,971.04. Following the sale, the senior vice president directly owned 7,202 shares in the company, valued at $493,264.98. This trade represents a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.88% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NGVT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Ingevity in a research report on Friday, July 17th. Wall Street Zen cut shares of Ingevity from a "strong-buy" rating to a "buy" rating in a report on Saturday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Ingevity has an average rating of "Hold" and an average price target of $80.00.

Ingevity Trading Up 4.2%

NGVT opened at $73.16 on Friday. The business has a fifty day moving average price of $71.76 and a 200 day moving average price of $70.97. The company has a debt-to-equity ratio of 22.52, a current ratio of 1.61 and a quick ratio of 0.92. Ingevity Corporation has a 12 month low of $39.74 and a 12 month high of $79.29. The stock has a market capitalization of $2.54 billion, a price-to-earnings ratio of 49.77 and a beta of 1.16.

Ingevity (NYSE:NGVT - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.33 by $0.41. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.The company had revenue of $314.10 million for the quarter, compared to analyst estimates of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Sell-side analysts expect that Ingevity Corporation will post 5.05 earnings per share for the current fiscal year.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.